by Plus Therapeutics | Jun 4, 2025 | GBM
New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner A new article by Ariana Pelosci at Cancer Network highlights promising data from Plus Therapeutics’ ongoing Phase 1/2 ReSPECT-GBM clinical trial, which is...
by Plus Therapeutics | May 27, 2025 | GBM
Honoring National Gray Day: Advancing Brain Cancer Awareness and Research Today marks National Gray Day, a powerful observance during Brain Cancer Awareness Month dedicated to honoring the lives lost to brain cancer and standing in solidarity with patients, survivors,...
by Plus Therapeutics | May 15, 2025 | Uncategorized
Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast In case you missed it, Plus Therapeutics President and CEO Dr. Marc Hedrick recently joined Ayesha Rashid on the Xtalks Life Sciences Podcast to discuss the company’s...
by Plus Therapeutics | May 14, 2025 | LM
New Data on REYOBIQ™ for Leptomeningeal Metastases Presented at the NMN Conference! Plus Therapeutics is pleased to announce that new clinical data on its lead investigational therapy, REYOBIQ™ (rhenium Re 186 obisbemeda), was presented at the Nuclear Medicine and...
by Plus Therapeutics | May 1, 2025 | GBM, LM, PBC, Uncategorized
Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus...
Recent Comments